<DOC>
	<DOCNO>NCT00980538</DOCNO>
	<brief_summary>The primary objective continue provision etravirine ( ETR ) patient previously receive ETR clinical pediatric trial sponsor collaboration Janssen Research &amp; Development , continue benefit use ETR , country ETR commercially available pediatric use , reimburse , access another source ( e.g . access program government program ) , patient eligible ongoing trials/programs ETR .</brief_summary>
	<brief_title>TMC125-TiDP35-C239 - Continued Access Etravirine ( ETR ) Treatment Experienced HIV-1 Infected Children Adolescents</brief_title>
	<detailed_description>This open label continue access trial HIV-1 infect child adolescent complete treatment pediatric clinical trial etravirine sponsor collaboration Janssen Research &amp; Development continue benefit use etravirine . At baseline visit , inclusion/exclusion criterion check confirm eligibility . Once eligibility criterion meet , patient either continue etravirine dose receive previous etravirine trial adjust dose deem necessary investigator . Etravirine dose adjustment base weight use dose guideline provide . Assessment visit recommend every three month . Adverse event lead treatment interruption discontinuation , adverse event least possibly related treatment etravirine , serious adverse event , pregnancy record visit . Treatment continue one follow criterion meet : investigator determine patient long benefit etravirine treatment ( e.g. , base viral load ) ; treatment limit toxicity ; loss follow-up ; patient withdrawal consent ; pregnancy ; termination program Sponsor ; etravirine becomes commercially available pediatric use , reimburse , access another source ( e.g . access program , government program ) region patient living , whichever occur first . Patients receive ETR , dose receive previous ETR trial , weight base dose adjustment necessary . 16 &lt; 20 kg :100 mg b.i.d . ( 4 tablet 25 mg b.i.d . 1 tablet 100 mg b.i.d ) . 20 &lt; 25 kg:125 mg b.i.d . ( 5 tablet 25 mg b.i.d . 1 tablet 100 mg + 1 tablet 25 mg b.i.d . ) 25 &lt; 30 kg:150 mg b.i.d . ( 6 tablet 25 mg b.i.d . 1 tablet 100 mg + 2 tablet 25 mg b.i.d ) . = 30 kg : 200 mg b.i.d . ( 8 tablet 25 mg b.i.d . 2 tablet 100 mg b.i.d )</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Patients meet follow criterion eligible trial : Documented HIV1 infection Younger 6 year age allow participate ETR dose recommendation age group available , sponsor notify investigator , applicable Ethics Committees , Health Authorities Successfully complete clinical pediatric trial ETR sponsor collaboration Janssen Research &amp; Development , continue receive benefit use ETR Patient ( appropriate , depend age ) parent ( ) legal representative ( ) sign Informed Consent Form ( ICF ) /Assent voluntarily Children inform program ask give assent ( appropriate , depend age ) Negative urine pregnancy test female childbearing potential Patients meet one follow criterion select : Any condition ( include limit alcohol drug use ) , opinion investigator could compromise patient 's safety adherence treatment ETR Any active clinically significant disease ( e.g. , pancreatitis , cardiac dysfunction ) find medical history , laboratory physical examination , investigator 's opinion , would compromise patient 's safety treatment ETR Previously demonstrate clinically significant allergy hypersensitivity ETR excipients ETR Pregnant breastfeed Nonvasectomized heterosexually active boy use safe effective birth control method , willing continue practice birth control method , trial 30 day end trial ( last intake investigational medication ) Girls , sexually active able become pregnant , use safe effective birth control method , willing continue practice birth control method , trial 30 day end trial ( last intake investigational medication )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TMC125-TiDP35-C239</keyword>
	<keyword>TMC125-C239</keyword>
	<keyword>TMC125</keyword>
	<keyword>HIV</keyword>
	<keyword>Etravirine</keyword>
	<keyword>Intelence</keyword>
	<keyword>IntelenceTM</keyword>
</DOC>